Martin Shkreli, the “pharma bro” in prison for defrauding investors, faces a lawsuit filed by the Federal Trade Commission and New York attorney general’s office for an alleged scheme to preserve his monopoly for the drug Daraprim, whose price increased by more than 4,000% in one day.
The lawsuit accuses a company that Shkreli once ran of buying the rights in 2015 to Daraprim, which is used to treat toxoplasmosis – a disease resulting from infection with a parasite – and quickly raising the price from $17.50 per tablet to $750 while taking steps to ensure there would not be a cheaper generic version of the medicine.
A lawyer for Shkreli, 36, did not respond to a request for comment. Shkreli is slated for release in September 2023, according to the Federal Bureau of Prisons.
Martin Shkreli shamelessly exploited and mocked people with AIDS and if I could wear his tears he shed in that courtroom in a vial around my neck i’d spend whole afternoons idly dandling it by a silver chain and watching it catch the glint of the midsummer sun
— Anthony Oliveira (@meakoopa) March 9, 2018
Jailed ‘Pharma Bro’ Martin Shkreli is SUED by federal and state authorities for ‘scheme’ to restrict and hike the price of life-saving HIV/Aids drug
via https://t.co/OzqfjGIyAx https://t.co/DDMI7BbYU1
— Dayna Liffey (@DaynaLiffey) January 28, 2020